This Medudy course is a video tutorial for physicians on the topic of "Resmetirome in NASH with liver fibrosis". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
Resmetirome is an oral, liver-targeted, beta-selective thyroid hormone receptor agonist. It is in development for the treatment of NASH with liver fibrosis and aims to restore liver tissue.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this course you will know
- the clinical background and relevance of the research question under investigation
- the study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
